$IONS News

HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $125 Price Target

Citigroup Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $115

Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100

Barclays Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $115

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $125

Ionis Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance

Ionis Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance above estimates.

Ionis Pharmaceuticals Raises FY2026 Sales Guidance from $800.000M-$825.000M to $875.000M-$900.000M vs $815.735M Est

Ionis Pharmaceuticals Q1 Adj. EPS $(0.30) Beats $(0.91) Estimate, Sales $246.000M Beat $195.628M Estimate

TD Cowen Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $108

Canaccord Genuity Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $110

Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $130

Ionis Pharma To Present Additional Results From Pivotal Study Of Zilganersen In Children And Adults Living With AxD At 2026 AAN Annual Meeting

B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $111

Barclays Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $106

Ionis Pharmaceuticals shares are trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $110 to $120. Also, Needham raised its price target on the stock from $103 to $105.